Ulsepan (pantoprazole) as an effective mean for preventing erosive and ulcerative lesions of the gastroduodenal zone in patients undergoing surgical interventions on digestive system

O.Yu. Usenko, M.V. Manoilo, I.V. Babii


Background. The purpose was to study the problem of erosive and ulcerative lesions of the upper gastrointestinal tract, the functional mechanisms for the protection of gastric mucosal barrier and to compare the effectiveness of the drugs used for prevention. Materials and methods. The study analyzed the experience of treatment of 58 patients who underwent surgical intervention. All patients were prevented from developing erosive and ulcerative lesions of the gastroduodenal zone using proton pomp inhibitors (intraoperatively and in the early postoperative period), their effectiveness was compared. Results. According to the study, Ulsepan (pantoprazole) compared with omeprazole has a greater efficacy in regulating the pH of the stomach and preventing the occurrence of stress lesions of the mucous membrane of the upper gastrointestinal tract. Conclusions. Ulsepan (pantoprazole) is an effective and safe mean for preventing erosive and ulcerative lesions in patients at risk during surgical interventions.


erosive and ulcerative lesions; stress ulcers; Ulsepan; pantoprazole


Constantin V.D., Paun S., Ciofoaia W., Budu V., Socea B. Multimodal management of upper gastrointestinal blee­ding caused by stress gastropathy // J. Gastrointestin. Lіver Dis. — 2009 Sep. — 18(3). — 279-84.

Гельфанд А.Н., Мартынов В.А., Гурьянов В.А., Шипилова О.С. Профилактика стресс-повреждений желудочно-кишечного тракта у больных в критических состояниях // Consilium Medicum. — 2005. — № 6. — 16-20.

Cook D., Guyatt G. Prophylaxis against Upper Gastrointestinal Bleeding in Hospitalized Patients // N. Engl. J. Med. — 2018 Jun 28. — 378(26). — 2506-2516. doi: 10.1056/NEJMra1605507.

Fiddian-Green R.G., McGough E., Pittenger G., Rothman E. Predictive value of intramural pH and other risk factors for massive bleeding from stress ulceration // Gastroenterology. — 1983. — 85(3). — 613-620.

Knight A., Bihari D., Tinker J. Stress ulceration in the critically ill patient // Br. J. Hosp. Med. — 1985. — 33(4). — 216-219.

Chen C., Shi Y., Zhang X.P., Zhang P.D. Risk factors associated with stress ulcer bleeding in postoperative rectal cancer patients // Chin. J. Gastrointest. Surg. — 2012. — 12. — 1277-1281.

Mutlu G.M., Mutlu E.A., Factor P. GI complications in patients receiving mechanical ventilation // Chest. — 2001. — 119. — 1222-1241.

Powell D.W. Barrier function of epithelia // American Journal of Physiology. — 1981. Осt. DOI: 10.1152/ajpgi.1981.241.4.G275.

Ritchie W.P. Prostaglandins: A surgeon’s perspective // Dig. Dis. Sci. — 1986. — 31. — S. 32-4.

Wedemeyer R.S., Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update // Drug Saf. — 2014 Apr. — 37(4). — 201-11. doi: 10.1007/s40264-014-0144-0.

Захарова Н.В. Ингибиторы протонной помпы с позиции эффективности и безопасности // Врач. — 2013. — T. 10. — С. 10-13.

Bliesath H., Huber R., Hartmann M., Lühmann R., Wurst W. Dose linearity of the pharmacokinetics of the new H+/K(+)-ATPase inhibitor pantoprazole after single intravenous administration // Int. J. Clin. Pharmacol. Ther. — 1996 May. — 34 (Suppl. 1). — S18-24.

Dammann H.G., Burkhardt F. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion // Eur. J. Gastroenterol. Hepatol. — 1999. — 11(11). — 1277-82.

Geus W.P., Mathot R.A., Mulder P.G. Pharmacodyna­mics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects // Aliment. Pharmacol. Ther. — 2000. — 14(8). — 1057-64.

Allen M.E., Kopp B.J., Erstad B.L. Stress ulcer prophylaxis in the postoperative period // Am. J. Health-System Pharm. — 2004 March. — 6. — 588-596.

Hartmann M., Ehrlich A., Fuder H., Lühmann R., Emeklibas S., Timmer W., Wurst W., Lücker P.W. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole // Aliment. Pharmacol. Ther. — 1998. — 12(10). — 1027-32.

Morris J., Karlstadt R., Blatcher D. et al. Intermittent intravenous pantoprazole rapidly achieves and maintains gastric pH > 40 compared with continuous infusion H2-receptor antagonist in intensive care unit patients // Crit. Care Med. — 2001. — 29. — A147.

Huber R., Hartmann M., Bliesath H. et al. Pharmacokinetics of pantoprazole in man // Int. J. Clin. Pharmacol. Ther. — 1996. — 34(5). — 185-94.

Andersson T., Cederberg C., Heggelund A. The pharmacokinetics of single and repeated once daily dose of 10, 20 and 40 mg omeprazole as enteric coated granules // Drug Invest. — 1991. — 3. — 45-52.

Leontiadis G.I., Sharma V.K., Howden C.W. Proton pump inhibitor treatment for acute peptic ulcer bleeding // Cochrane Database Syst. Rev. — 2010 May 12. — 5. — CD002094. doi: 10.1002/14651858.CD002094.pub4.

Brzozowski T., Magierowska K., Magierowski M., Ptak-Belowska A., Pajdo R., Kwiecien S., Olszanecki R., Korbut R. Recent Advances in the Gastric Mucosal Protection Against Stress-induced Gastric Lesions. Importance of Renin-angiotensin Vasoactive Metabolites, Gaseous Mediators and Appetite Peptides // Curr. Pharm. Des. — 2017. — 23(27). — 3910-3922. doi: 10.2174/1381612823666170220160222.

Whittle B.J.R., Gustavsson S., Kumar D., Graham D.Y. Protective mechanisms of the gastric mucosa. — Edinburgh, London, Madrid: Churchill Livingstone, 1992. — 81-101.

Яковенко Е.П., Яковенко А.В. Виразки, патогенетичні підходи до терапії // Фараматека. — 2008. — № 6. — S. 62-67.

Buendgens L., Koch A., Tacke F. Prevention of stress-related ulcer bleeding at the intensive care unit: Risks and benefits of stress ulcer prophylaxis // World J. Crit. Care Med. — 2016 Feb 4. — 5(1). — 57-64. doi: 10.5492/wjccm.v5.i1.57

Copyright (c) 2019 EMERGENCY MEDICINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта